Resources>Blog>Drug Delivery Systems for Antibody-Based Therapies

Drug Delivery Systems for Antibody-Based Therapies

Biointron 2024-01-17 Read time: 2 mins
Antibody-Based-Therapies.jpg
Image credit: DOI: 10.1038/s41551-021-00698-w

Antibody-based therapies have emerged as powerful tools in the fight against cancer, providing targeted treatment options with reduced side effects. To further enhance their efficacy, researchers have been exploring the use of drug delivery systems (DDS) for the controlled release of antibodies. DDS would produce various benefits in drug efficacy, including improved convenience, reduced toxicity, and enhanced treatment outcomes.1 With the advancement of nanotechnology and increasing focus on antibody-related dosage forms, the development of advanced antibody delivery systems holds promise for cancer patients.

Typically, antibody-based drugs are administered through intravenous routes, although there are risks with infusion-related reactions. To improve patient medication convenience, DDSs controlled release may use strategies such as subcutaneous injections, local depot formulations, inhalation powders, and oral systems.2 Another example are hydrogels, which studies have shown to be a potential DDS, controlling the release of antibody-streptavidin conjugates from the agarose-desthiobiotin hydrogels via controlled dissolution of sparingly soluble biotin derivatives.3

At Biointron, we are dedicated to accelerating antibody discovery, optimization, and production. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.


References:

  1. Chen, Z., Kankala, R. K., Yang, Z., Li, W., Xie, S., Li, H., Chen, Z., & Zou, L. (2022). Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. Theranostics, 12(8), 3719-3746. https://www.thno.org/v12p3719.htm

  2. Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020). Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics, 12(10). https://www.mdpi.com/1999-4923/12/10/999

  3. Huynh, V., & Wylie, R. G. (2018). Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels. Angewandte Chemie International Edition, 57(13), 3406-3410. https://onlinelibrary.wiley.com/doi/10.1002/anie.201713428

Subscribe to our Blog

Recommended Articles

Immune-Stimulating Antibody Conjugates (ISACs): Challenges and Future Prospects

Antibody-drug conjugates (ADCs) have transformed cancer therapy by selectively d……

Mar 14, 2025
A Global Overview of Therapeutic Antibody Development

Monoclonal antibodies (mAbs) have significantly improved the treatment landscape……

Mar 12, 2025
World ADC 2025 – London: Highlights and Event Recap

The 15th World ADC London was held on March 3-6, 2025. Antibody-drug conjugates ……

Mar 10, 2025
Antibody CRO Services: Advancing Antibody Discovery & Production

Discover leading antibody CRO services for therapeutic and diagnostic applicatio……

Mar 06, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.